THE EXPERIENCE OF PARENTERAL METHOTREXATE TREATMENT IN A PATIENT WITH PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS
https://doi.org/10.15690/vsp.v11i6.505
Abstract
The article contains a history case of early onset of pauciarticular juvenile rheumatoid arthritis resistant to standard immunosuppressive treatment with methotrexate at a dose of 15 mg/m2 per week orally, with development of contractures and destructive changes in the joints. The resistance was successfully overcome with conversion to intravenous introduction at a dose of 25 mg/m2 per week. After 6 months of treatment acute inflammatory changes in the joins, arthralgia and morning joint stiffness were arrested, as well as laboratory markers of the active stage of disease lowered. After 12 months of treatment the motion capacity was completely restored in 3 of 4 affected joints. The non-active stage and remission were registered in 6 and 12 months, respectively. The remission has remained for 18 months.
About the Authors
T. V. Sleptsova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. I. Alexeeva
Scientific Centre of Children Health, RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University,
Russian Federation
Russian Federation
R. V. Denisova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
T. M. Bzarova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
K. B. Isaeva
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. V. Mitenko
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
References
1. Cassidy J., Petty R. Texbook of paediatric rheumatology, 6th еdn. Saunders Elsevier. 2010. 9 p.
2. Алексеева Е. И., Литвицкий П. Ф. Ревматоидный артрит. Этиология, патогенез. Клиника. Алгоритмы диагностики и лечения. М.: Веди. 2007. 359 с.
3. Kroot E. J., van Leeuwen M. A., van Rijswijk M. H., Prevoo M. L., van 't Hof M. A., van De Putte L. B., van Riel P. L. No increased mortality in patient with rheumatoid arthritis: up to 10 years of follow-up from disease onset. Ann. Rheum. Dis. 2000; 59: 954–958.
4. Клинические рекомендации. Ревматология. Под ред. Е. Л. Насонова. М.: ГЭОТАР-Медиа. 2005. С. 25–71, 120–140.
5. Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., Dewitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care & Res. 2011; 63 (4): 465–482.
6. Fleischmann R. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Exp. Opin. Drug. Saf. 2003; 2 (4): 347–365.
7. Алексеева Е. И., Шахбазян И. Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. Аутоиммунные болезни. 2002; 5: 127.
8. Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294 (13): 1671–1684.
9. Насонов Е. Л. Противовоспалительная терапия ревматических болезней. М.: М–Сити. 1996. 345 с.
10. Tynjala P., Vahasalo P., Tarkiainen M., Kroger L., Aalto K., Malin M., Putto-Laurila A., Honkanen V., Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann. Rheum. Dis. 2011; 70.
11. Visvanathan S., Wagner C., Marini J. C., Lovel D. J., Martini A., Petty R., Cuttica R., Woo P., Espada G., Gattorno M., Apaz M. T., Baildam E., Fasth A., Gerloni V., Lahdenne P., Quartier P., Saurenmann R., Travers S., Mendelsohn A., Xu S., Giannini E. H., Ruperto N. for the Paediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr. Rheum. 2010; 8: 24.
12. Alarcon G. S. Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders. In: Arthritis and Allied Conditions. A Text book of rheumatology, 13th edn. W. J. Koopman (еd.). Baltimore, Philadelphia, London: Williams & Wilkins. 1997; 1: 679–698.
13. Cronstein B. N. The mechanism of action of methotrexate. Rheum. Dis. Clin. North. Am. 1997; 23: 739–755.
14. Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis. Rheumatism. 2002; 49 (1): 20–24.
15. Cassidy J. T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis. J. Pediatr. 1998; 133: 179–180.
16. Klein A., Kaul I., Foeldvari I., Ganser G., Urban A., Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care & Res. (Hoboken). 2012; 64 (9): 1349–1356.
17. Ramanan A. V., Whitworth P., Baildam E. M. Use of methotrexate in juvenile idiopathic arthritis. Arch. Dis. Child. 2003; 88: 197–200.
18. Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis. Therapy. 1999; 81: 766–772.
19. Giannini E. H., Brewer E. J., Kuzmina N., Shaikov A., Maximov A., Vorontsov I., Fink C. W., Newman A. J., Cassidy J. T., Zemel L. S. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA–USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N. Engl. J. Med. 1992; 326: 1043–1049.
20. Woo P., Southwood T. R., Prieur A. M., Dore C. J., Grainger J., David J., Ryder C., Hasson N., Hall A., Lemelle I. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43 (8): 1849–1857.
21. Silverman E., Mouy R., Spiegel L., Jung L. K., Saurenmann R. K., Lahdenne P., Horneff G., Calvo I., Szer I. S., Simpson K., Stewart J. A., Strand V. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N. Engl. J. Med. 2005; 352: 1655–1666.
22. Albertioni F., Flato B., Seideman P., Beck O., Vinje O., Peterson C., Eksborg S. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur. J. Clin. Pharmacol. 1995; 47 (6): 507–511.
23. Tukova J., Chladek J., Nemcova D., Chladkova J., Dolezalova P. Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2009; 27 (6): 1047–1053.
24. Ruperto N., Murray K. J., Gerloni V., Wulffraat N., de Oliveira S. K., Falcini F., Dolezalova P., Alessio M., Burgos-Vargas R., Corona F., Vesely R., Foster H., Davidson J., Zulian F., Asplin L., Baildam E., Consuegra J. G., Ozdogan H., Saurenmann R., Joos R., Pistorio A., Woo P., Martini A. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50: 2191–2201.
25. Alsufyani K., Ortiz-Alvarez O., Cabral D. A., Tucker L. B., Petty R. E., Malleson P. N. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J. Rheumatol. 2004; 31 (1): 179–182.
26. Kugathasan S., Newman A. J., Dahms B. B., Boyle J. T. Liver biopsy findings liver in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. J. Pediatr. 1996; 128 (1): 149–151.
27. Cron R. Q., Sherry D. D., Wallace C. A. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J. Pediatr. 1998; 132 (5): 901–902.
Review
For citations:
Sleptsova T.V., Alexeeva E.I., Denisova R.V., Bzarova T.M., Isaeva K.B., Mitenko E.V. THE EXPERIENCE OF PARENTERAL METHOTREXATE TREATMENT IN A PATIENT WITH PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS. Current Pediatrics. 2012;11(6):131-137. (In Russ.) https://doi.org/10.15690/vsp.v11i6.505
Views:
773
Email this article 
